The cell therapy developer sold 18.4 million shares at $18 apiece, within the high end of its projected $16 to $18 per share range. Allogene Therapeutics , which tackles cancer by engineering immune cells to make them fight the disease better , has raised $ 288 million in an auction on Nasdaq . The firm is one of a number of cancer with chimeric antigen receptor ( CAR - T ) therapies . It bought the US rights to the UCART19 cell therapy from Pfizer along with the rights to 16 other preclinical CR - T products . It is engineering allogenic cells taken from anonymous donors and the firm says such treatments could be cheaper and easier to make and give to patients than existing therapies . It also wants to expand CAR - T to more cancer types .
Allogene Therapeutics , which tackles cancer by engineering immune cells to make them fight the disease better , has raised $ 288 million in an auction on Nasdaq . The firm is one of a number of cancer with chimeric antigen receptor ( CAR - T ) therapies . It bought the US rights to the UCART19 cell therapy from Pfizer along with the rights to 16 other preclinical CR - T products . It is engineering allogenic cells taken from anonymous donors and the firm says such treatments could be cheaper and easier to make and give to patients than existing therapies . It also wants to expand CAR - T to more cancer types .